Press Release
Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome
Ashburn, Virginia, September 22nd, 2026, FinanceWire
– First-Ever Fast Track Designation Granted for a Peeling Skin Syndrome Therapy
– Second Fast Track Designation Granted to QRX003, in Addition to Netherton Syndrome
– Fast Track Designation Facilitates Development and Expedites Regulatory Review of Therapies Addressing Serious Conditions with Significant Unmet Medical Need
– Follows July 2026 FDA Clearance of the First-Ever IND Submitted for Peeling Skin Syndrome
– Phase 2/3 Study Expected to Initiate in 2H 2026, Enrolling up to 12 Pediatric and Adult Patients in the U.S. and Europe
– Peeling Skin Syndrome Currently Has No Approved Treatment
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to QRX003 for the treatment of Peeling Skin Syndrome (PSS). QRX003 is an investigational topical serine protease inhibitor lotion. Peeling Skin Syndrome is a rare genetic skin disease for which there is currently no approved treatment.
Key Facts
- Fast Track Designation applies to QRX003 for the treatment of Peeling Skin Syndrome.
- This is the first ever Fast Track Designation granted for a Peeling Skin Syndrome therapy.
- Peeling Skin Syndrome is the second indication for which QRX003 has received Fast Track Designation. The FDA granted Fast Track Designation to QRX003 lotion (4%) for the treatment of Netherton Syndrome on March 11, 2026.
- The designation follows FDA clearance in July 2026 of Quoin’s Investigational New Drug (IND) application for QRX003 in Peeling Skin Syndrome. Quoin submitted that IND on June 2, 2026, and it was the first IND ever submitted to the FDA for the disease.
- Quoin expects to initiate a Phase 2/3 clinical study of QRX003 in Peeling Skin Syndrome in the second half of 2026.
- The IND submission was supported by clinical observations from an ongoing investigator-led pediatric study in a single subject. Significant improvements in skin appearance along with positive changes in pruritus and a number of quality-of-life measures have been recorded. Treatment is ongoing and has continued for more than 15 months, with no adverse events reported.
- There is currently no approved treatment for Peeling Skin Syndrome.
“This is an important regulatory milestone for QRX003 and for a community that today has no approved treatment,” said Dr. Michael Myers, CEO and Co-Founder of Quoin Pharmaceuticals. “Quoin submitted the first IND ever filed with the FDA for Peeling Skin Syndrome, that IND was cleared in July, and QRX003 has now been granted Fast Track Designation for the disease. We expect to initiate our Phase 2/3 study in the second half of 2026, and we believe Fast Track status will allow us to work closely with the agency as we advance the first company-sponsored clinical study in this disease.”
Peeling Skin Syndrome Development Program
The planned Phase 2/3 study is expected to enroll up to 12 pediatric and adult patients with Peeling Skin Syndrome in the United States and Europe. In the study, QRX003 will be applied twice-daily to greater than 80% of patients’ body surface area (BSA) over a 48-week period, with an interim data review at 24 weeks. Quoin is targeting approval of QRX003 as a potential treatment for Peeling Skin Syndrome in 2028.
The IND submission was supported by clinical observations from an ongoing investigator-led pediatric study. The subject has achieved improvements across key objective severity endpoints, including the Modified Ichthyosis Area Severity Index (M-IASI), Investigator’s Global Assessment (IGA) as well as pruritus and a pediatric dermatology-specific quality-of-life measure (CDLQI). Treatment is ongoing, and after continued dosing with QRX003 for over 15 months, no adverse events have been reported.
About Fast Track Designation
The FDA’s Fast Track program is designed to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need. A therapy granted Fast Track Designation may benefit from more frequent interactions with the FDA, eligibility for rolling review of regulatory submissions, and potential qualification for Accelerated Approval and Priority Review, if relevant criteria are met.
About Peeling Skin Syndrome (PSS)
Generalized inflammatory peeling skin syndrome (PSS) is a rare autosomal recessive genodermatosis caused by loss-of-function disease-causing variants of the corneodesmosin gene (CDSN), resulting in excessive shedding of the superficial layers of the epidermis. Patients generally suffer from a variety of conditions including severe pain and chronic pruritus (itch). There is currently no approved treatment for PSS.
About QRX003
QRX003 is an investigational topical serine protease inhibitor lotion in late-stage development for Netherton Syndrome and other orphan skin diseases. QRX003 has been granted Orphan Drug, Rare Pediatric Disease, and Fast Track designations by the U.S. Food and Drug Administration, and Orphan Drug Designation in the European Union and Japan for Netherton Syndrome. QRX003 has also been granted Rare Pediatric Disease and Fast Track Designation by the FDA for Peeling Skin Syndrome. QRX003 lotion (4%) is currently being evaluated in Phase 2/3 whole-body clinical trials in patients with Netherton Syndrome. Quoin expects to initiate a Phase 2/3 clinical study of QRX003 in Peeling Skin Syndrome in the second half of 2026.
About Quoin Pharmaceuticals Ltd
Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities, and care teams. Quoin’s innovative pipeline is focused on two key platform products, QRX003 and QRX009, that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Pachyonychia Congenita, Gorlin Syndrome and Tuberous Sclerosis Complex, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibromas and others.
For more information, visit: www.quoinpharma.com or LinkedIn for updates.
Forward-Looking Statements
The Company cautions that statements in this press release that are not descriptions of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances, such as “expect,” “intend,” “hope,” “plan,” “potential,” “anticipate,” “look forward,” “believe,” “may,” and “will,” among others. This press release contains forward-looking statements. All statements that reflect the Company’s expectations, assumptions, projections, beliefs, or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to: Fast Track Designation facilitating development and expediting regulatory review of therapies addressing serious conditions with significant unmet medical need; plans to initiate a Phase 2/3 clinical study of QRX003 in Peeling Skin Syndrome in the second half of 2026; Fast Track status allowing Quoin to work closely with the FDA to advance the first company-sponsored clinical study in Peeling Skin Syndrome; the study expecting to enroll up to 12 pediatric and adult patients with Peeling Skin Syndrome in the United States and Europe; QRX003 expected to be applied twice-daily to greater than 80% of a patients’ body surface area over a 48-week period, with an interim data review at 24 weeks; targeting approval of QRX003 as a potential treatment for Peeling Skin Syndrome in 2028; therapies granted Fast Track Designation benefiting from more frequent interactions with the FDA, eligibility for rolling review of regulatory submissions, and potential qualification for Accelerated Approval and Priority Review, if relevant criteria are met; and Quoin’s products in development collectively having the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Pachyonychia Congenita, Gorlin Syndrome, Tuberous Sclerosis Complex, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibroma and others. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the Company’s ability to pursue its regulatory strategy; the Company’s ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements; the Company’s ability to complete clinical trials on time and achieve desired results and benefits as expected; and other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.
Contacts
Jeff Ramson
jramson@pcgadvisory.com
Michael Myers
mmyers@quoinpharma.com
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Injective Partners With the University of Tokyo, Japan’s Top University, to Advance Blockchain Innovation
New York, New York, November 16th, 2026, FinanceWire
The collaboration connects Injective’s financial blockchain infrastructure with the University of Tokyo’s expertise in blockchain research and education, to accelerate education, research and technical talent development with the university’s Endowed Chair.
Injective Foundation today announced an agreement with the University of Tokyo, Japan’s top-ranked university, to support blockchain education and explore collaboration in onchain finance, research, and talent development. Signed through the university’s Graduate School of Engineering, the Memorandum of Understanding establishes a framework for collaboration with its Endowed Chair for Blockchain Innovation.
Founded in 1877 as Japan’s first national university, the University of Tokyo ranks first in Japan and 27th globally in the Times Higher Education World University Rankings 2027. The collaboration connects Injective’s experience building financial blockchain infrastructure with an academic program dedicated to blockchain research, practical implementation and the development of future engineers and entrepreneurs.
Injective and the Endowed Chair are planning a collaborative lecture examining blockchain infrastructure, financial market design and onchain applications. The session will introduce Injective’s Layer 1 architecture and its applications across trading, real-world asset tokenization and settlement, with a hands-on component for participants interested in blockchain development.
The planned session will connect the technical design of blockchain systems with the financial activity they support. Participants will examine how infrastructure can enable assets to be represented, traded and settled onchain, alongside the engineering and market-design considerations involved in developing these applications.
“Financial infrastructure advances when talented people have the tools and knowledge to build something better,” said Eric Chen, CEO of Injective Labs. “Working with Japan’s top university brings Injective’s expertise in onchain markets into one of the world’s leading academic environments. We want future builders to understand how this infrastructure works and gain practical experience developing the financial applications it makes possible.”
Established in November 2018, the Endowed Chair for Blockchain Innovation combines research and development, practical implementation and talent development. Its work draws on computer science, cryptography and economics to examine the capabilities and limitations of blockchain systems, including privacy, scalability and the reliability of data brought onchain.
The collaboration brings an industry perspective to that academic work. Injective’s architecture will provide a concrete system for participants to study and discuss, connecting blockchain theory with the design of infrastructure for financial applications.
Beyond the planned lecture, the two sides may explore research opportunities related to real-world asset tokenization and onchain financial structures relevant to Japan. Other activities under consideration include workshops, public events, a future hackathon and programs bringing together researchers, developers and financial practitioners.
“Understanding onchain finance requires us to examine both the technology and the financial systems it interacts with,” said Kyohei Shibano, Project Researcher at the University of Tokyo. “Our collaboration with Injective offers an opportunity to bring those perspectives together. Through education and practical discussion, we hope to deepen participants’ understanding of blockchain applications and identify important questions for future research.”
For Injective, supporting the Endowed Chair is an investment in the knowledge and skills needed to develop onchain financial markets. The planned lecture provides an initial focus for the collaboration, with further educational activities and potential research to be explored under the agreement.
About Injective
Injective is the first blockchain purpose-built for finance, enabling users, institutions, and AI agents to trade, tokenize, and transact at scale. Proudly made in America, Injective provides foundational blockchain infrastructure for global markets, with embedded financial primitives spanning stablecoins, real-world assets, payments, and programmable perpetuals through a unified onchain engine. Injective is used by Fortune 500 companies, banks, fintechs, and governments to power an open economy where any asset can be accessed anytime, from anywhere. Builders can deploy across multiple virtual machines like WASM and EVM, connect to native financial modules, and launch markets with deep liquidity from day one.
About the University of Tokyo
The University of Tokyo was established in 1877 as Japan’s first national university. UTokyo offers undergraduate and graduate education across nearly all academic disciplines and conducts research across the arts and sciences. Its academic community works across three core campuses in Hongo, Komaba, and Kashiwa.
Learn more at www.u-tokyo.ac.jp/en.
Media Contact
C-Suite Media Strategies
Kristopher Conesa
kconesa@csuitepr.com
305-975-5934
Contact
Sarah Cohen
sarah@sjc-pr.com
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Freedom Holding Corp. Reports 81% Increase in Quarterly Revenue to $910.1 Million
New York, United States, November 16th, 2026, FinanceWire
Banking and insurance revenue more than doubled; net income rose 29% and total assets reached $16.6 billion as the company continued expanding its customer base and international presence
Freedom Holding Corp. (NASDAQ: FRHC), an international financial services and technology group, today announced its unaudited consolidated financial results for the second quarter of fiscal year 2027, covering the three months ended September 30, 2026.
Revenue reached $910.1 million for the quarter, compared with $503.6 million a year earlier, an increase of 81%. Growth was driven largely by strong performances in banking and insurance. Net income increased 29% to $46.1 million from $35.7 million, while diluted earnings per share rose to $0.76 from $0.58.
For the first half of fiscal year 2027, Freedom reported revenue of $1.64 billion, up 60% from a year earlier, while net income reached $77.7 million. Freedom’s total assets reached $16.61 billion as of September 30, 2026, a 26% increase from $13.16 billion at the end of March.
“Our second-quarter results reflect the strength of our diversified business model and the momentum we are building across financial services and technology,” said Timur Turlov, Chief Executive Officer of Freedom Holding Corp. “With quarterly revenue increasing 81%, driven by particularly strong growth in banking and insurance, we continue to see the benefits of expanding our customer reach and connecting more services within the Freedom ecosystem. Our entry into Türkiye’s banking market and strategic acquisitions in education and technology mark important steps in our long-term strategy to build an integrated platform that serves customers across multiple markets.”
Business Segment Results
Banking and insurance accounted for much of Freedom’s revenue growth, with both segments more than doubling revenue compared with a year earlier. Banking revenue nearly tripled to $298.1 million, up 182% from $105.7 million a year earlier. The increase was driven in part by higher interest income, supported by an expanding loan portfolio, growth in securities investments, and gains from securities trading and foreign exchange transactions.
Revenue in the insurance segment rose 133% to $299.2 million, putting insurance slightly ahead of banking for the quarter. Much of the growth came from the pension annuityinsurance business, which recorded an increase in new policies and related premium inflows. Revenue in the Other segment rose 161% to $90.5 million, supported by telecommunications, online retail and other digital services. The brokerage segment recorded a 5% decline in revenue to $222.2 million from $234.9 million a year earlier, mainly due to weaker results from securities trading and foreign exchange operations.
Across the group, interest income increased 53% to $323.9 million, while net insurance revenue rose 148% to $254.8 million. Fee and commission income increased 12% to $148.5 million.
Expansion of the Customer Base and Digital Ecosystem
Freedom continued to expand its customer base, particularly across its banking and digital services. The banking segment reported 5.934 million customers at the end of September, an increase of 908,000 since the start of the fiscal year in April. The number of brokerage customers rose from 858,000 to 907,000 over the same six-month period. The Other segment, including technology and lifestyle services, had 1.553 million customers at the end of September, compared with 1.105 million at the end of March.
Freedom is also developing an integrated ecosystem that allows customers to access multiple financial and digital services through the group’s platforms. Banking customers can use investment, insurance, payment and other products within the same ecosystem. In Kazakhstan, Freedom has been developing this model through its SuperApp, which combines financial services and everyday transactions.
Acquisitions in Banking, Education and Technology
Freedom continued to expand its operations through acquisitions during the first half of the fiscal year. On July 31, the group completed the acquisition of a combined 99.3% ownership interest in Freedom Bank TR (Turkish Bank), a licensed Turkish commercial bank that has operated in Türkiye since 1982. The acquisition provides Freedom with an established platform for expanding its digital banking and financial services offerings in the Turkish market. The group’s acquisition activity extended beyond financial services. In September, Freedom acquired a 60% stake in Bilim Group, a major educational technology provider in Kazakhstan and Central Asia.
During the first half of the fiscal year, Freedom also acquired German chess software developer ChessBase GmbH and Estonia-based Wallet Solutions OÜ, a virtual asset service provider. These acquisitions support Freedom’s strategy to expand its international presence, strengthen its digital ecosystem and integrate complementary businesses into its existing operations.
About Freedom Holding Corp.
Freedom Holding Corp. provides financial services in 27 countries, including Kazakhstan, the United States, multiple EU countries, Uzbekistan, and Armenia. The Company’s principal executive office is located in New York City.In Kazakhstan, Freedom is actively developing its financial and digital ecosystem, which includes Freedom Bank, Freedom Broker, the insurance companies Freedom Life and Freedom insurance, as well as a lifestyle segment that features Arbuz.kz, Freedom Ticketon, and Aviata.
Freedom Holding Corp. shares are traded on the U.S. technology exchange NASDAQ, the Kazakhstan Stock Exchange (KASE), and the Astana International Exchange (AIX) under the ticker symbol FRHC. Freedom Holding Corp. is regulated by the U.S. Securities and Exchange Commission (SEC), and its common stock is included in the Russell 1000, Russell Midcap, Russell 3000, and Nasdaq Composite indices.
Contact
Head of Public Relations
Natalia Kharlashina
Freedom Holding Corp.
prglobal@ffin.kz
+77013641454
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
American Battery Materials and XTC Lithium Limited Extend Letter of Intent for Strategic Partnership on the Carachi Lithium Project to June 30, 2027
Greenwich, Connecticut, USA, November 16th, 2026, FinanceWire
American Battery Materials, Inc. (OTC PINK: BLTH) (“ABM”), a Delaware corporation focused on the exploration and development of critical battery materials, and XTC Lithium Limited (“XTC”), an Australian company, today announced the extension of their non-binding Letter of Intent (LOI). The LOI outlines the principal terms of a proposed partnership to advance the Carachi Lithium Project in Catamarca Province, Argentina.
The Carachi Lithium Project is held by XTC’s wholly owned Argentine subsidiary, XTC Lithium Argentina SAR. It consists of multiple exploration properties located within Argentina’s Lithium Triangle, one of the world’s most significant regions for lithium brine resources. Lithium is a critical input for batteries used in electric vehicles and energy storage systems.
Under the terms of the extended LOI, ABM has the opportunity to earn up to a 50% interest in the Carachi Lithium Project. Once ABM has secured a 10% interest, it will have the right to enter into a formal joint venture agreement with XTC to continue exploration and development of the mining tenements.
“This Letter of Intent is an important step in our strategy to expand our presence in the global lithium market,” said David E. Graber, CEO of American Battery Materials. “Partnering with XTC Lithium gives us access to a promising project in the heart of the Lithium Triangle. XTC has an experienced operating team that is personally invested in the project and has a strong track record of identifying, advancing, and financing lithium assets through to successful outcomes. We look forward to working together to unlock the project’s potential.”
John Featherby, Chairman of XTC Lithium Limited, added, “We are pleased to continue our collaboration with ABM on the Carachi Lithium Project. Their focus on sustainable development and their complementary expertise make them a strong partner as we work to advance the project.”
The proposed transaction remains subject to the negotiation and execution of a definitive agreement, the satisfaction of all closing conditions contained therein, receipt of all necessary statutory, corporate, and regulatory approvals, and the availability of financing. There can be no assurance that a definitive agreement will be signed or that the transaction will be completed on the terms outlined in the LOI or at all.
Both companies view the potential partnership as aligned with the growing global demand for lithium driven by the expansion of electric vehicles and clean energy infrastructure. The parties will continue working toward finalizing definitive documentation and obtaining required approvals.
About American Battery Materials, Inc.
American Battery Materials, Inc., headquartered in Greenwich, Connecticut, is a U.S.-based company focused on the exploration, acquisition, and development of lithium and other battery materials essential to the global energy transition. ABM is committed to responsible practices and creating long-term value through strategic partnerships and project advancement.
About XTC Lithium Limited
XTC Lithium Limited, based in Wollstonecraft, New South Wales, Australia, is an exploration and development company with a focus on lithium resources in Argentina. Through its subsidiary XTC Lithium Argentina SAR, the company is advancing projects in the Lithium Triangle.
Forward-Looking Statements
This press release contains forward-looking statements regarding the potential partnership between ABM and XTC, the development of the Carachi Lithium Project, and related matters. These statements are subject to risks and uncertainties, including the possibility that a definitive agreement is not executed, that required approvals are not obtained, or that other conditions are not satisfied. Actual results may differ materially. Neither company undertakes any obligation to update these statements except as required by applicable law.
Contact
American Battery Materials, Inc.
ir@americanbatterymaterials.com
+1 800-998-7962
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
-
Press Release5 days ago
Midwest Ragdolls Explains Why Playful Kitten Biting Is Often Misunderstood
-
Press Release5 days ago
ARCPE Holding, LLC Highlights the Importance of Understanding Local Real Estate Market Conditions
-
Press Release4 days ago
Red Banyan CEO Evan Nierman Leads High-Stakes Communications Workshop at NASDDDS Annual Conference
-
Press Release1 week ago
Altegio Announces Open Platform Connecting Beauty and Wellness Businesses With AI Agents at Web Summit 2026
-
Press Release3 days ago
IntelliVIX Wins Two CES 2027 Innovation Awards, Showcasing Global Competitiveness in Safety AI
-
Press Release3 days ago
Rifstone Capital LLC Advances Institutional Research Platform with Expanded Global Allocation Framework
-
Press Release5 days ago
Dasher Personalized Running Highlights Personalized Half Marathon Training Plans Focused on Injury Prevention and Sustainable Progress
-
Press Release6 days ago
Rantizo (Nasdaq: RNTZ) Advances U.S. Production of Heavy-Lift Autonomous Drones After $258.8 Million Acquisition, Targets California’s $61.2 Billion Agricultural Market
